3B Blackbio DX Ltd
₹ 1,664
-1.58%
22 Nov
- close price
About
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
Key Points
- Market Cap ₹ 1,428 Cr.
- Current Price ₹ 1,664
- High / Low ₹ 1,910 / 660
- Stock P/E 33.2
- Book Value ₹ 287
- Dividend Yield 0.18 %
- ROCE 21.0 %
- ROE 15.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has a good return on equity (ROE) track record: 3 Years ROE 17.2%
Cons
- Company has high debtors of 179 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 | 22 | 19 | 17 | 16 | 23 | 23 | 29 | 227 | 81 | 62 | 74 | 89 | |
| 19 | 21 | 18 | 16 | 14 | 18 | 16 | 20 | 77 | 44 | 33 | 41 | 43 | |
| Operating Profit | 1 | 1 | 1 | 2 | 3 | 5 | 7 | 9 | 150 | 37 | 29 | 33 | 46 |
| OPM % | 6% | 6% | 7% | 9% | 16% | 23% | 31% | 32% | 66% | 46% | 47% | 44% | 51% |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 7 | 7 | 13 | 14 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 0 | 0 | 0 | 1 | 5 | 7 | 10 | 152 | 43 | 35 | 44 | 59 |
| Tax % | 34% | 14% | 23% | 23% | 19% | 24% | 25% | 23% | 25% | 26% | 27% | 28% | |
| 0 | 0 | 0 | 0 | 1 | 3 | 5 | 8 | 114 | 32 | 26 | 32 | 43 | |
| EPS in Rs | 0.62 | 0.59 | 0.36 | 0.51 | 1.76 | 5.35 | 8.18 | 10.24 | 151.66 | 42.89 | 34.55 | 37.40 | 50.53 |
| Dividend Payout % | -0% | -0% | -0% | -0% | 17% | 9% | 6% | 7% | 6% | 24% | 8% | 8% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 26% |
| 3 Years: | -31% |
| TTM: | 35% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 56% |
| 5 Years: | 44% |
| 3 Years: | -34% |
| TTM: | 61% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 70% |
| 5 Years: | 82% |
| 3 Years: | 56% |
| 1 Year: | 133% |
| Return on Equity | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 33% |
| 3 Years: | 17% |
| Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 |
| Reserves | 3 | 4 | 4 | 4 | 5 | 12 | 16 | 25 | 125 | 146 | 185 | 214 | 238 |
| 6 | 7 | 8 | 8 | 9 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 1 | |
| 7 | 7 | 7 | 6 | 6 | 6 | 8 | 9 | 59 | 37 | 19 | 24 | 22 | |
| Total Liabilities | 23 | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 269 |
| 4 | 4 | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 7 | 7 | |
| CWIP | -0 | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 |
| Investments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 1 | 59 | 93 | 92 | 117 | 133 |
| 19 | 20 | 21 | 21 | 22 | 26 | 32 | 40 | 130 | 93 | 114 | 123 | 129 | |
| Total Assets | 23 | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 269 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1 | 0 | 0 | 1 | 1 | 2 | 4 | 7 | 98 | 37 | 20 | 27 | |
| 0 | -0 | -0 | -0 | -0 | -1 | -1 | -1 | -70 | -28 | 15 | -20 | |
| -0 | 0 | -0 | -1 | -0 | 0 | -1 | 1 | -2 | -15 | -5 | -4 | |
| Net Cash Flow | -1 | 0 | -0 | 0 | -0 | 1 | 2 | 7 | 26 | -6 | 30 | 3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 220 | 213 | 262 | 283 | 321 | 259 | 290 | 252 | 56 | 136 | 200 | 179 |
| Inventory Days | 149 | 120 | 145 | 143 | 175 | 164 | 141 | |||||
| Days Payable | 220 | 189 | 218 | 203 | 186 | 69 | 66 | |||||
| Cash Conversion Cycle | 149 | 144 | 188 | 223 | 310 | 259 | 290 | 252 | 56 | 136 | 296 | 253 |
| Working Capital Days | 214 | 218 | 274 | 312 | 377 | 308 | 351 | 302 | 67 | 169 | 248 | 216 |
| ROCE % | 8% | 7% | 7% | 7% | 13% | 24% | 28% | 31% | 162% | 27% | 19% | 21% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov - Newspaper Advertisement- Regulation 47 of SEBI (LODR) Regulations, 2015
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 13 Nov
-
Announcement under Regulation 30 (LODR)-Investor Presentation
13 Nov - Investor presentation on financial performance and business outlook.
-
Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September 2024
13 Nov - Board approved unaudited financial results for Q2 FY2024.
-
Board Meeting Outcome for The Board Have Considered And Approved The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September 2024
13 Nov - Approved unaudited financial results for Q2 FY2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Nov 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Sep 2021TranscriptNotesPPT
-
Jul 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Sep 2020TranscriptNotesPPT
-
Jul 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
May 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Jul 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
Business Segments[1][2]
A) Diagnostics Business (81% of FY23 revenue)
3BDL is part of an Indo-Spanish JV and was formed by amalgamation with its parent company Kilpest India Limited. Company is an ISO 13485:2016 certified, GMP-compliant biotech R&D organization and is engaged in the design, development, manufacturing, and commercialization of Rapid tests, PCR-based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, NGS-based Molecular Diagnostic Kit